|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HTATSF1 |
Gene summary for HTATSF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HTATSF1 | Gene ID | 27336 |
| Gene name | HIV-1 Tat specific factor 1 | |
| Gene Alias | TAT-SF1 | |
| Cytomap | Xq26.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | O43719 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27336 | HTATSF1 | LZE2T | Human | Esophagus | ESCC | 2.06e-06 | 8.49e-01 | 0.082 |
| 27336 | HTATSF1 | LZE4T | Human | Esophagus | ESCC | 1.38e-10 | 4.61e-01 | 0.0811 |
| 27336 | HTATSF1 | LZE5T | Human | Esophagus | ESCC | 9.96e-03 | 5.13e-01 | 0.0514 |
| 27336 | HTATSF1 | LZE7T | Human | Esophagus | ESCC | 3.64e-03 | 5.56e-01 | 0.0667 |
| 27336 | HTATSF1 | LZE8T | Human | Esophagus | ESCC | 2.50e-02 | 2.78e-02 | 0.067 |
| 27336 | HTATSF1 | LZE20T | Human | Esophagus | ESCC | 9.95e-08 | 2.83e-01 | 0.0662 |
| 27336 | HTATSF1 | LZE22T | Human | Esophagus | ESCC | 8.26e-03 | 4.91e-01 | 0.068 |
| 27336 | HTATSF1 | LZE24T | Human | Esophagus | ESCC | 7.84e-29 | 9.18e-01 | 0.0596 |
| 27336 | HTATSF1 | LZE21T | Human | Esophagus | ESCC | 2.87e-04 | 3.53e-01 | 0.0655 |
| 27336 | HTATSF1 | LZE6T | Human | Esophagus | ESCC | 2.61e-02 | 2.38e-01 | 0.0845 |
| 27336 | HTATSF1 | P1T-E | Human | Esophagus | ESCC | 5.94e-14 | 9.58e-01 | 0.0875 |
| 27336 | HTATSF1 | P2T-E | Human | Esophagus | ESCC | 7.79e-65 | 1.03e+00 | 0.1177 |
| 27336 | HTATSF1 | P4T-E | Human | Esophagus | ESCC | 1.88e-28 | 7.86e-01 | 0.1323 |
| 27336 | HTATSF1 | P5T-E | Human | Esophagus | ESCC | 2.19e-18 | 4.55e-01 | 0.1327 |
| 27336 | HTATSF1 | P8T-E | Human | Esophagus | ESCC | 7.16e-41 | 7.95e-01 | 0.0889 |
| 27336 | HTATSF1 | P9T-E | Human | Esophagus | ESCC | 1.59e-33 | 7.54e-01 | 0.1131 |
| 27336 | HTATSF1 | P10T-E | Human | Esophagus | ESCC | 2.78e-69 | 1.23e+00 | 0.116 |
| 27336 | HTATSF1 | P11T-E | Human | Esophagus | ESCC | 1.12e-16 | 7.10e-01 | 0.1426 |
| 27336 | HTATSF1 | P12T-E | Human | Esophagus | ESCC | 1.29e-50 | 9.63e-01 | 0.1122 |
| 27336 | HTATSF1 | P15T-E | Human | Esophagus | ESCC | 1.85e-23 | 5.13e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:0019079111 | Esophagus | ESCC | viral genome replication | 102/8552 | 131/18723 | 4.31e-14 | 2.19e-12 | 102 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:001603212 | Liver | Cirrhotic | viral process | 203/4634 | 415/18723 | 5.40e-27 | 3.76e-24 | 203 |
| GO:001905812 | Liver | Cirrhotic | viral life cycle | 148/4634 | 317/18723 | 1.12e-17 | 1.64e-15 | 148 |
| GO:001907912 | Liver | Cirrhotic | viral genome replication | 69/4634 | 131/18723 | 5.77e-12 | 3.98e-10 | 69 |
| GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HTATSF1 | SNV | Missense_Mutation | c.613N>A | p.Glu205Lys | p.E205K | O43719 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| HTATSF1 | SNV | Missense_Mutation | c.856N>A | p.Glu286Lys | p.E286K | O43719 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| HTATSF1 | SNV | Missense_Mutation | novel | c.2172G>T | p.Arg724Ser | p.R724S | O43719 | protein_coding | deleterious_low_confidence(0.03) | benign(0.001) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| HTATSF1 | SNV | Missense_Mutation | c.1007G>C | p.Trp336Ser | p.W336S | O43719 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD | |
| HTATSF1 | SNV | Missense_Mutation | c.1807N>A | p.Glu603Lys | p.E603K | O43719 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HTATSF1 | SNV | Missense_Mutation | c.1355N>T | p.Ser452Ile | p.S452I | O43719 | protein_coding | deleterious_low_confidence(0.01) | benign(0.003) | TCGA-AO-A0JG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| HTATSF1 | SNV | Missense_Mutation | c.2002N>T | p.Ala668Ser | p.A668S | O43719 | protein_coding | tolerated_low_confidence(0.1) | benign(0.058) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| HTATSF1 | SNV | Missense_Mutation | novel | c.761G>A | p.Arg254Gln | p.R254Q | O43719 | protein_coding | tolerated(0.08) | benign(0.014) | TCGA-B6-A401-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| HTATSF1 | SNV | Missense_Mutation | c.1402N>A | p.Glu468Lys | p.E468K | O43719 | protein_coding | tolerated_low_confidence(0.14) | benign(0.432) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HTATSF1 | SNV | Missense_Mutation | c.1582N>A | p.Glu528Lys | p.E528K | O43719 | protein_coding | tolerated_low_confidence(0.15) | benign(0.013) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |